Key Points Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead. Launching newer medicines could help Pfizer overcome the obstacles ahead. 10 stocks we like better than Pfizer › The past few years have been challenging for Pfizer (NYSE: PFE) . The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Albert Bourla, Pfizer's headwinds are easing. Is he right? Image source: The Motley Fool. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.